<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00142818</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-12756-3</org_study_id>
    <secondary_id>P50DA012756-03</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00142818</nct_id>
  </id_info>
  <brief_title>Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence</brief_title>
  <acronym>Mod-Nal</acronym>
  <official_title>A Phase II, Double-blind, Placebo-Controlled, Pilot Trial of the Combination of Modafinil and Naltrexone for the Treatment of Cocaine and Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyle Kampman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modafinil is a medication that may enhance mood and increase energy in cocaine addicts, which&#xD;
      may be useful in preventing cocaine relapse. Naltrexone is a medication that is currently&#xD;
      used to treat drug and alcohol addiction. A combination of these two medications may be&#xD;
      beneficial in reducing drug and alcohol use in individuals undergoing substance abuse&#xD;
      treatment. The purpose of this study is to evaluate the effectiveness of modafinil and&#xD;
      naltrexone, alone and in combination, at reducing drug and alcohol use in individuals&#xD;
      addicted to cocaine and alcohol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine and alcohol addiction are serious health problems with no available medical treatment&#xD;
      for preventing relapse. Past research has shown that individuals who are addicted to both&#xD;
      cocaine and alcohol typically respond poorly to conventional substance abuse treatment.&#xD;
      Little attention has been directed towards how best to treat these individuals. Naltrexone is&#xD;
      a medication that is currently used to treat drug and alcohol addiction. It acts by blocking&#xD;
      the &quot;high&quot; feeling produced by drugs and alcohol. Modafinil, another medication, enhances&#xD;
      mood, increases energy, and improves concentration in people with narcolepsy. Preliminary&#xD;
      research has shown that it may produce similar effects to cocaine, thereby potentially&#xD;
      countering the symptoms of cocaine withdrawal. Cognitive Behavioral Coping Skills Therapy&#xD;
      (CBT), a form of therapy that aims to alter an individual's patterns of behavior and drug&#xD;
      use, is also an important component of substance abuse treatment. The purpose of this study&#xD;
      is to compare the effectiveness of CBT plus placebo, CBT plus modafinil, CBT plus naltrexone,&#xD;
      and CBT plus a combination of modafinil and naltrexone at reducing cocaine and alcohol use in&#xD;
      individuals addicted to both substances.&#xD;
&#xD;
      This 14-week study will enroll individuals addicted to both cocaine and alcohol. During a&#xD;
      1-week screening period, potential participants will be required to complete a detoxification&#xD;
      program, including stopping all cocaine and alcohol use. Participants will also undergo a&#xD;
      physical exam and an electrocardiogram. Blood will be drawn for laboratory tests, and urine&#xD;
      tests will be used to screen for the presence of drugs and alcohol. Individuals who complete&#xD;
      the screening and meet all study requirements will be permitted to participate in the&#xD;
      treatment phase of the study. During the 13-week treatment phase, participants will be&#xD;
      randomly assigned to receive modafinil, naltrexone, a combination of modafinil and&#xD;
      naltrexone, or placebo. All participants will attend a CBT session once a week. Study visits&#xD;
      will take place twice a week. At each visit, a urine test and breathalyzer will be used to&#xD;
      screen for the presence of alcohol and drugs. Participants will also complete standardized&#xD;
      psychological questionnaires to measure drug and alcohol craving, treatment services&#xD;
      received, severity of illness, and withdrawal symptoms. In addition, participants will meet&#xD;
      weekly with a nurse practitioner, who will dispense study medications, monitor adverse&#xD;
      events, and evaluate the participant's clinical status. A follow-up evaluation will occur 6&#xD;
      months following the end of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use (Measured by Timeline Follow Back and Urine Screen From Week 2-week 14)</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Days of Heavy Drinking (Measured by Timeline Follow Back Starting at Week Two Through Week 14</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Alcohol-Related Disorders</condition>
  <condition>Alcoholism</condition>
  <condition>Cocaine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Naltrexone plus modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nal + Mod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>150 mg daily for males; 100 mg daily for females</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_label>Naltrexone plus modafinil</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>400 mg daily</description>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_label>Naltrexone plus modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400 mg and/or 100-150 mg placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        4.1 Inclusion Criteria&#xD;
&#xD;
          1. Male and females, 18 years of age or older.&#xD;
&#xD;
          2. Meets DSM-IV criteria for current diagnoses of cocaine and alcohol dependence,&#xD;
             determined by the SCID-IV.&#xD;
&#xD;
          3. In the past 30 days, used no less than $200-worth of cocaine and meets the following&#xD;
             drinking criteria as measured by the Timeline Followback (TLFB) (Sobell, 1995):&#xD;
&#xD;
               1. drank within 30 days of intake day,&#xD;
&#xD;
               2. reports a minimum of 48 standard alcoholic (avg. 12 drinks/wk) in a consecutive&#xD;
                  30-day period over the 90-day period prior to starting intake (i.e., a minimum of&#xD;
                  40% days drinking), and&#xD;
&#xD;
               3. has 2 or more days of heavy drinking (defined as 5 or more drinks per day in&#xD;
                  males and 4 or more drinks per day in females) in this same pre-treatment period.&#xD;
&#xD;
          4. 72 consecutive hours of abstinence from alcohol, determined by self-reports and&#xD;
             confirmed by a negative breathalyzer tests, and a Clinical Institute Withdrawal Scale&#xD;
             for Alcohol (CIWA-AR) (Sullivan, 1989) score below eight. Subjects will be encouraged&#xD;
             to achieve 72 consecutive hours of abstinence, however, subjects who have achieved&#xD;
             between 48 and 72 consecutive hours of abstinence will be included with the approval&#xD;
             of the principal investigator. We anticipate that these subjects will comprise less&#xD;
             than 5% of total enrolled subjects. Subjects will be given 2 additional weeks beyond&#xD;
             the screening week to attain the appropriate period of alcohol abstinence prior to&#xD;
             randomization.&#xD;
&#xD;
          5. Lives a commutable distance from the TRC and agrees to attend all research visits&#xD;
             including follow-up visits.&#xD;
&#xD;
          6. Speaks, understands, and prints in English&#xD;
&#xD;
          7. Ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Abstinent from cocaine or alcohol for 30 consecutive days prior to signing consent&#xD;
             form.&#xD;
&#xD;
          2. Meets DSM IV criteria for dependence on any substance other than cocaine and alcohol&#xD;
             (except nicotine), determined by the SCID.&#xD;
&#xD;
          3. Needs treatment with any psychoactive medications including any anti-seizure&#xD;
             medications (with the exception of diphenhydramine used sparingly, if necessary, for&#xD;
             sleep).&#xD;
&#xD;
          4. Meets current or lifetime DSM-IV criteria for schizophrenia or any psychotic disorder&#xD;
             or organic mental disorder. Subject meets current DSM-IV diagnosis of any other&#xD;
             clinically significant psychiatric disorder that will interfere with study&#xD;
             participation.&#xD;
&#xD;
          5. Has evidence of a history of significant hematological, pulmonary, endocrine,&#xD;
             cardiovascular, renal or gastrointestinal disease (including a history of myocardial&#xD;
             infarction, mitral valve prolapse, left ventricular hypertrophy, uncontrolled&#xD;
             hypertension).&#xD;
&#xD;
          6. Severe physical or medical illnesses such as AIDS, active hepatitis, significant&#xD;
             hepatocellular injury as evidenced by elevated total bilirubin levels (&gt;1.3 mg/dl),or&#xD;
             elevated levels (over 4.5x normal) of aspartate aminotransferase (AST), and serum&#xD;
             glutamic-pyruvic transaminase (SGPT) after the required 3 days of abstinence.&#xD;
&#xD;
          7. Use of an investigational medication in the 30 days prior to randomization.&#xD;
&#xD;
          8. History of hypersensitivity to modafinil or naltrexone&#xD;
&#xD;
          9. Receiving chronic therapy with any drug known to interact adversely with either&#xD;
             modafinil or naltrexone including propranolol, phenytoin, warfarin, diazepam&#xD;
&#xD;
         10. Took a monoamine oxidase inhibitor within 30 days of randomization.&#xD;
&#xD;
         11. Is female and tests positive on a pregnancy test, is contemplating pregnancy in the&#xD;
             next 6 months, is nursing, or is not using an effective contraceptive method (if&#xD;
             relevant). Acceptable methods of contraception include barrier methods (diaphragm or&#xD;
             condom with spermicide, female condom), intrauterine progesterone contraceptive&#xD;
             system, levonorgrestrel implant, and medroxyprogeterone acetate contraceptive&#xD;
             injection, copper IUD, vaginal contraceptive film, cervical cap, contraceptive foam.&#xD;
&#xD;
         12. Current use of an oral contraceptive without other acceptable barrier method of&#xD;
             contraception.&#xD;
&#xD;
         13. Received therapy with any opiate substitute (methadone, LAAM, buprenorphine) within 60&#xD;
             days of randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle M. Kampman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104 6178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <results_first_submitted>August 12, 2014</results_first_submitted>
  <results_first_submitted_qc>August 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Kyle Kampman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alcohol Abuse</keyword>
  <keyword>Cocaine Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Alcohol-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ModNal</title>
          <description>Nal + Mod&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females&#xD;
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone and Placebo</title>
          <description>Nal&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
        </group>
        <group group_id="P3">
          <title>Modafinil and Placebo</title>
          <description>Mod&#xD;
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="P4">
          <title>Double Placebo</title>
          <description>Placebo&#xD;
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ModNal</title>
          <description>Nal + Mod&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females&#xD;
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone and Placebo</title>
          <description>Nal&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
        </group>
        <group group_id="B3">
          <title>Modafinil and Placebo</title>
          <description>Mod&#xD;
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="B4">
          <title>Double Placebo</title>
          <description>Placebo&#xD;
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use (Measured by Timeline Follow Back and Urine Screen From Week 2-week 14)</title>
        <time_frame>13 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ModNal</title>
            <description>Nal + Mod&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females&#xD;
Modafinil: 400 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Nal&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
          </group>
          <group group_id="O3">
            <title>Modafinil and Placebo</title>
            <description>Mod&#xD;
Modafinil: 400 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Double Placebo</title>
            <description>Placebo&#xD;
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use (Measured by Timeline Follow Back and Urine Screen From Week 2-week 14)</title>
          <units>number of cocaine negative urine samples</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="8.4"/>
                    <measurement group_id="O2" value="7.2" spread="8.1"/>
                    <measurement group_id="O3" value="10.1" spread="9.4"/>
                    <measurement group_id="O4" value="10.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Days of Heavy Drinking (Measured by Timeline Follow Back Starting at Week Two Through Week 14</title>
        <time_frame>13 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Modafinil Plus Naltrexone</title>
            <description>Nal + Mod&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females&#xD;
Modafinil: 400 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone</title>
            <description>Nal&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
          </group>
          <group group_id="O3">
            <title>Modafinil</title>
            <description>Mod&#xD;
Modafinil: 400 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days of Heavy Drinking (Measured by Timeline Follow Back Starting at Week Two Through Week 14</title>
          <units>mean percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" spread="4.4"/>
                    <measurement group_id="O2" value="35.1" spread="4.2"/>
                    <measurement group_id="O3" value="33.6" spread="4.2"/>
                    <measurement group_id="O4" value="33.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ModNal</title>
          <description>Nal + Mod&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females&#xD;
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone and Placebo</title>
          <description>Nal&#xD;
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
        </group>
        <group group_id="E3">
          <title>Modafinil and Placebo</title>
          <description>Mod&#xD;
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="E4">
          <title>Double Placebo</title>
          <description>Placebo&#xD;
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Exacerbation of cocaine and alcohol</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression or Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Arrested for Homicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kyle Kampman</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-222-3200 ext 109</phone>
      <email>kampman@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

